Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.86 EPS.
Milestone Pharmaceuticals Trading Down 2.0 %
MIST opened at $1.98 on Monday. The firm’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.67. The firm has a market cap of $105.59 million, a PE ratio of -2.44 and a beta of 1.78. Milestone Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $2.75. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. Equities research analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.
Institutional Inflows and Outflows
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Featured Stories
- Five stocks we like better than Milestone Pharmaceuticals
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Best Aerospace Stocks Investing
- What Does the Future Hold for Eli Lilly?
- How Investors Can Find the Best Cheap Dividend Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.